Tregs: A Therapeutic Target for the Treatment of Portal Fibrosis?-Reference-Cited by-同舟云学术

Tregs: A Therapeutic Target for the Treatment of Portal Fibrosis?

Published:2015-05-14 Issue:7 Volume:60 Page:1878-1880
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Xue Yuhua,Michalopoulos George

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-015-3687-8.pdf

Reference10 articles.

1. Michalopoulos GK, Barua L, Bowen WC. Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology. 2005;41:535–544.

2. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139–145.

3. Desmet VJ. Ludwig symposium on biliary disorders—part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc. 1998;73:80–89.

4. Sanchez-Munoz D, Castellano-Megias VM, Romero-Gomez M. Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. Dig Liver Dis. 2007;39:262–266.

5. Roh YS, Park S, Lim CW, Kim B. Depletion of Foxp3+ regulatory T cells promotes profibrogenic milieu of cholestasis-induced liver injury. Dig Dis Sci. (Epub ahead of print). doi: 10.1007/s10620-014-3438-2 .

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tryptophan-kynurenine profile in pediatric autoimmune hepatitis;Immunologic Research;2019-01-21

2. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets;World Journal of Gastroenterology;2016